ANAPTYSBIO, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
ANAPTYSBIO, INC. (ANAB) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 27.36 million shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-05-04
- ANAPTYSBIO, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 27.36M shares, a 0.36% increase year-over-year.
- ANAPTYSBIO, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 27.35M shares, a 0.66% increase year-over-year.
- ANAPTYSBIO, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 27.32M shares, a 0.95% increase year-over-year.
- ANAPTYSBIO, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 27.28M shares, a 0.94% increase year-over-year.
- ANAPTYSBIO, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 27.30M shares, a 0.90% increase from fiscal 2019.
- ANAPTYSBIO, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 27.06M shares, a 9.67% increase from fiscal 2018.
- ANAPTYSBIO, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 24.67M shares, a 24.72% increase from fiscal 2017.
- ANAPTYSBIO, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2017 was 19.78M shares, a 650.17% increase from fiscal 2016.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-03-31 | 27.36M shares 10-Q · filed 2021-05-04 | 27.36M shares derived: average of 2 quarters · filed 2021-05-04 | 27.34M shares derived: average of 3 quarters · filed 2021-05-04 | 27.33M shares derived: average of 4 quarters · filed 2021-05-04 |
| 2020-12-31 | 27.35M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 27.33M shares derived: average of 2 quarters · filed 2021-02-25 | 27.32M shares derived: average of 3 quarters · filed 2021-02-25 | 27.30M shares 10-K · filed 2021-02-25 |
| 2020-09-30 | 27.32M shares 10-Q · filed 2020-11-04 | 27.30M shares derived: average of 2 quarters · filed 2020-11-04 | 27.29M shares 10-Q · filed 2020-11-04 | 27.26M shares derived: average of 4 quarters · filed 2021-05-04 |
| 2020-06-30 | 27.28M shares 10-Q · filed 2020-08-10 | 27.27M shares 10-Q · filed 2020-08-10 | 27.24M shares derived: average of 3 quarters · filed 2021-05-04 | 27.19M shares derived: average of 4 quarters · filed 2021-05-04 |
| 2020-03-31 | 27.26M shares 10-Q · filed 2021-05-04 | 27.22M shares derived: average of 2 quarters · filed 2021-05-04 | 27.16M shares derived: average of 3 quarters · filed 2021-05-04 | 27.13M shares derived: average of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | 27.17M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 27.11M shares derived: average of 2 quarters · filed 2021-02-25 | 27.08M shares derived: average of 3 quarters · filed 2021-02-25 | 27.06M shares 10-K · filed 2021-02-25 |
| 2019-09-30 | 27.06M shares 10-Q · filed 2020-11-04 | 27.04M shares derived: average of 2 quarters · filed 2020-11-04 | 27.02M shares 10-Q · filed 2020-11-04 | 26.97M shares derived: average of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | 27.03M shares 10-Q · filed 2020-08-10 | 27.00M shares 10-Q · filed 2020-08-10 | 26.94M shares derived: average of 3 quarters · filed 2021-02-25 | 26.24M shares derived: average of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | 26.98M shares 10-Q · filed 2020-05-06 | 26.89M shares derived: average of 2 quarters · filed 2021-02-25 | 25.98M shares derived: average of 3 quarters · filed 2021-02-25 | 25.47M shares derived: average of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | 26.81M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 25.48M shares derived: average of 2 quarters · filed 2021-02-25 | 24.96M shares derived: average of 3 quarters · filed 2021-02-25 | 24.67M shares 10-K · filed 2021-02-25 |
| 2018-09-30 | 24.15M shares 10-Q · filed 2019-11-08 | 24.04M shares derived: average of 2 quarters · filed 2019-11-08 | 23.96M shares 10-Q · filed 2019-11-08 | 23.75M shares derived: average of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | 23.93M shares 10-Q · filed 2019-08-08 | 23.87M shares 10-Q · filed 2019-08-08 | 23.62M shares derived: average of 3 quarters · filed 2020-03-02 | 22.81M shares derived: average of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | 23.80M shares 10-Q · filed 2019-05-07 | 23.46M shares derived: average of 2 quarters · filed 2020-03-02 | 22.44M shares derived: average of 3 quarters · filed 2020-03-02 | 21.89M shares derived: average of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | 23.12M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | 21.75M shares derived: average of 2 quarters · filed 2020-03-02 | 21.26M shares derived: average of 3 quarters · filed 2020-03-02 | 19.78M shares 10-K · filed 2020-03-02 |
| 2017-09-30 | 20.38M shares 10-Q · filed 2018-11-08 | 20.33M shares derived: average of 2 quarters · filed 2018-11-08 | 18.67M shares 10-Q · filed 2018-11-08 | |
| 2017-06-30 | 20.27M shares 10-Q · filed 2018-08-07 | 17.80M shares 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | 15.29M shares 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | 2.64M shares 10-K · filed 2019-02-28 | |||
| 2016-03-31 | 2.63M shares 10-Q · filed 2017-05-12 | |||
| 2015-12-31 | 2.55M shares 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |